Trial · NCT04006145
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16 | Elobixibat | -0.57 | Standard Error 0.125 | mmol/L | |
| Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16 | Placebo | -0.17 | Standard Error 0.134 | mmol/L | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Elobixibat | TEAEs | 13 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Placebo | TEAEs | 10 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Elobixibat | TESAEs | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Placebo | TESAEs | 0 | Participants | |
| Absolute Change From Baseline to Week 16 in Liver Fat Fraction | Elobixibat | -0.43 | Standard Error 1.203 | percent of liver fat | |
| Absolute Change From Baseline to Week 16 in Liver Fat Fraction | Placebo | 0.09 | Standard Error 1.299 | percent of liver fat | |
| Absolute Change From Baseline to Week 16 in Total Liver Fat | Elobixibat | -2.80 | Standard Error 36.240 | milliliter | |
| Absolute Change From Baseline to Week 16 in Total Liver Fat | Placebo | 7.95 | Standard Error 39.146 | milliliter | |
| Change From Baseline to Week 16 in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Gamma-glutamyl Transferase (GGT) | Elobixibat | ALT | 5.04 | Standard Error 3.914 | Units/liter |
| Change From Baseline to Week 16 in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Gamma-glutamyl Transferase (GGT) | Placebo | ALT | 1.05 | Standard Error 3.969 | Units/liter |
| Change From Baseline to Week 16 in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Gamma-glutamyl Transferase (GGT) | Elobixibat | AST | 2.21 | Standard Error 2.250 | Units/liter |
| Change From Baseline to Week 16 in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Gamma-glutamyl Transferase (GGT) | Placebo | AST | 0.96 | Standard Error 2.359 | Units/liter |
| Change From Baseline to Week 16 in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Gamma-glutamyl Transferase (GGT) | Elobixibat | GGT | 5.12 | Standard Error 2.009 | Units/liter |
| Change From Baseline to Week 16 in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Gamma-glutamyl Transferase (GGT) | Placebo | GGT | -1.73 | Standard Error 2.108 | Units/liter |
| Change From Baseline to Week 16 in High-density Lipoprotein (HDL) Cholesterol, Non-high-density Lipoprotein Cholesterol and Triglycerides | Elobixibat | HDL cholesterol | 0.03 | Standard Error 0.047 | millimoles/liter |
| Change From Baseline to Week 16 in High-density Lipoprotein (HDL) Cholesterol, Non-high-density Lipoprotein Cholesterol and Triglycerides | Placebo | HDL cholesterol | -0.05 | Standard Error 0.049 | millimoles/liter |
| Change From Baseline to Week 16 in High-density Lipoprotein (HDL) Cholesterol, Non-high-density Lipoprotein Cholesterol and Triglycerides | Elobixibat | Non-HDL cholesterol | -0.75 | Standard Error 0.154 | millimoles/liter |
| Change From Baseline to Week 16 in High-density Lipoprotein (HDL) Cholesterol, Non-high-density Lipoprotein Cholesterol and Triglycerides | Placebo | Non-HDL cholesterol | -0.23 | Standard Error 0.162 | millimoles/liter |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04006145/results